Vaccines prevent severe COVID-19, even from Delta variant--study | Inquirer News

Vaccines prevent severe COVID-19, even from Delta variant–study

/ 02:17 PM October 11, 2021

vaccine bubbles

FREER MOVEMENT FOR VACCINEES Residents avail themselves of COVID-19 vaccines in Marikina City on Tuesday. Some government and business leaders have called for the setup of so-called vaccine bubbles to stimulate the economy and allow fully inoculated employees to return to work. —NIÑO JESUS ORBETA

PARIS — Vaccination is highly effective at preventing severe cases of Covid-19, even against the Delta variant, a vast study in France has shown.

The research published Monday — focusing on prevention of severe Covid and death, not infection — looked at 22 million people over 50 and found those who had received jabs were 90 percent less likely to be hospitalized or die.

Article continues after this advertisement

The results confirm observations from the US, the UK and Israel, but researchers say it is the largest study of its kind so far.

FEATURED STORIES

Looking at data collected starting in December 2020, when France launched its jab campaign, the researchers compared the outcomes of 11 million vaccinated people with 11 million unvaccinated subjects.

They formed pairs matching an unvaccinated individual with a vaccinated counterpart from the same region and of the same age and sex, tracking them from the date of the vaccinated person’s second jab to July 20.

Article continues after this advertisement

Starting 14 days after a second dose, a vaccinated subjects’ risk of severe Covid was reduced by 90 percent, according to the research conducted by Epi-Phare, an independent medicines safety research group that works closes with the French government.

Article continues after this advertisement

Vaccination appears to be nearly as effective against for the Delta variant, with 84 percent protection for people 75 and older and 92 percent for people 50-75.

Article continues after this advertisement

That estimate, however, is only based on a month of data, since the variant became dominant in France only in June.

“The study should be followed up to include results from August and September,” epidemiologist Mahmoud Zureik, the head of Epi-Phare, told AFP.

Article continues after this advertisement

The study covers vaccination with the Pfizer/BioNtech, Moderna and AstraZeneca jabs, but not Jannsen which was authorized much later and is far less widely used in France.

The results also suggest that over the period of study — up to five months — vaccination protection against severe Covid did not diminish.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Coronavirus, France, Health

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.